EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Evofem Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026
- Market cap
- $865.23K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
77.1%+82.1 pts over 5 years
Operating margin
16.7%+23250.8 pts over 5 years
Net margin
1.9%+31909.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.2% | +6.2% | +114.4% | – | |
| Gross profit | +0.2% | +7.8% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 16.6% | -1675.9% | -0.5% | |
| Return on assets | -49.2% | -205.9% | 1.8% | |
| Current ratio | 13.86 | 1.26 | 0.18 | |
| Interest coverage | -11.6× | -50.3× | 1.4× | |
| Inventory turnover | – | 0.1× | 3.4× | |
| Capex to revenue | – | 505.4% | 0.0% | |
| Diluted shares | 0M | 0M | 6.42B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Evofem Biosciences generated $231.92M from operations and spent $3.32M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$231.92M
Used
$3.32M
Capital expenditure$3.30M99%Dividends$00%Share buybacks$18.00K1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1.9%
×Asset turnover0.92×
×Equity multiplier-0.30×
=Return on equity, FY2025-0.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 1.9% | 0.92× | -0.30× | -0.5% |
| FY2024 | -45.8% | 1.13× | -0.25× | 12.9% |
| FY2023 | 290.8% | 1.02× | -0.26× | -76.6% |
| FY2022 | -455.5% | 0.50× | -0.38× | 87.1% |
| FY2021 | -2489.0% | 0.11× | -1.48× | 398.6% |
| FY2020 | -31907.8% | 0.01× | 8.14× | -1675.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$391.00K
- Cash generatingOperating cash flow above zero-$1.99M
- Return on assets improvedROA up on the prior year-83.9% → 1.6%
- Earnings backed by cashOperating cash flow above net income-$1.99M vs $391.00K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.17 → 0.18
- No dilutionShare count did not rise80M → 6.42B
- Gross margin improvedGross margin up on the prior year80.20% → 77.12%
- More efficientAsset turnover rose1.83 → 0.85